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ABSTRACT
Cardiovascular disease (CVD) is a major cause of morbidity and mortality in chronic kidney disease (CKD) patients. This 
study aimed to determine the roles of CVD biomarkers in CKD patients. This was a case-control study which recruited 
consecutive patients with stage 2-4 CKD patients with and without CVD. Serum levels of highly-sensitive C reactive protein 
(hs-CRP), cystatin C (CysC), asymmetrical dimetylarginine (ADMA) and symmetrical dimethylarginine (SDMA) were 
measured. Sixty two stage 2-4 CKD patients with a mean age of 60.3 ± 10.4 years were recruited. Twenty three (37.1%) 
of them had CVD. Those CKD patients with CVD were older (64.1±8.0 vs 58.1± 1.1, p<0.05) and had significantly higher 
systolic blood pressure (139.4 ± 16.2 vs 129.4 ± 14.8 mmHg, p<0.05). Diabetic patients had 8 times (95% CI 1.25-51.77, 
p< 0.05) higher risk to develop CVD. CKD patients with CVD had a higher serum creatinine (185.0 ± 54.1 vs 154.1 ± 54.4 
μmol/L, p<0.05), a lower estimated glomerular filtration rate (33.7 ± 12.2 vs 42.2 ± 14.5 mL/min/1.73m2 p<0.05) and a 
lower triglyceride levels (1.3 (1.1-1.7) vs 1.8 (1.4-2.3) mmol/L, p<0.05), compared to those without CVD. Fasting blood 
sugar was 7.1 ± 2.7 mmol/L in CVD group and 6.3 ± 1.6 mmol/L in non CVD group (p>0.05). There were no differences 
in their mean serum levels of hs-CRP, CysC, ADMA and SDMA. Risk factors including age, diabetes mellitus, hypertension 
and renal functions were still the most important CVD risk factors in CKD patients. 
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ABSTRAK
Penyakit kardiovaskular (CVD) adalah punca utama morbiditi dan kematian kepada pesakit buah pinggang kronik (CKD). 
Kajian ini bertujuan untuk menentukan peranan penanda biologi kardiovaskular dalam kalangan pesakit CKD. Ini adalah 
satu kajian kes-kawalan yang melibatkan pesakit CKD peringkat 2-4 dengan dan tanpa CVD. Tahap serum protein reaktif 
C sensitif berdaya tinggi (hs-CRP), sistatin C (CysC), asimetri dimetilarginin (ADMA) dan simetri dimetilarginin (SDMA) 
diukur. Enam puluh dua pesakit CKD peringkat 2-4 dengan purata umur 60.3 ± 10.4 tahun telah diambil. Dua puluh 
tiga (37.1%) daripada mereka mempunyai CVD. Pesakit CKD dengan CVD yang lebih tua (64.1 ± 8.0 berbanding 58.1 ± 
1.1, p<0.05) dan mempunyai tekanan darah sistolik yang lebih tinggi (139.4 ± 16.2 berbanding 129.4 ± 14.8 mmHg, 
p<0.05). Seperti yang dijangka pesakit kencing manis mempunyai 8 kali (95% CI 1.25-51.77, p<0.05) risiko yang lebih 
tinggi untuk mendapat CVD. Pesakit CKD dengan CVD mempunyai nilai serum kreatinin yang  lebih tinggi (185.0 ± 54.1 
berbanding 154.1 ± 54.4 μmol/L, p<0.05 lebih rendah anggaran kadar penapisan glomerul (33.7 ± 12.2 berbanding 
42.2 ± 14.5 mL/min/1.73 m2, p<0.05 dan  tahap trigliserida yang lebih rendah (1.3 (1.1-1.7) berbanding 1.8 (1.4-2.3) 
mmol/L, p<0.05) berbanding dengan mereka yang tidak mempunyai CVD. Paras gula berpuasa adalah 6.8 ± 2.5 mmol/L 
di dalam kumpulan CVD dan 7.0 ± 2.9 mmol/L dalam kumpulan bukan CVD (p>0.05). Tidak ada perbezaan dalam tahap 
serum  hs-CRP, CycC, ADMA dan SDMA mereka. Kesimpulan daripada kajian ini adalah faktor risiko CVD  tradisi seperti 
umur, penyakit kencing manis, darah tinggi dan fungsi buah pinggang masih adalah faktor risiko CVD yang paling 
penting dalam pesakit CKD.  
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INTRODUCTION
Cardiovascular disease (CVD) is one of the most important 
causes of worldwide preventable morbidity and mortality 
(Hennekens 1998). CVD has become the major cause of 
mortality in Malaysia and mortality rates due to CVD 
continue to rise (Khor 2001; WHO 2014).  Epidemiological 
studies have identified many major clinical risk factors 
for CVD which include diabetes mellitus, hypertension, 
dyslipidaemia and smoking. Despite measures to control 
these risk factors and advances in therapeutic measures, 
CVD mortality continues its relentless rise. Hence CVD 
and its treatment as well as the treatment/prevention of its 
risk factors pose a huge economic burden to our country. 
Patients with chronic kidney disease (CKD) have an 
unacceptably high prevalence and incidence of CVD. CKD 
patients, regardless of age, race, or gender, suffer from 
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a 10- to 100-fold greater incidence of death from CVD 
compared to their normal counterparts in the general 
population. Moreover, 39% of CKD patients have had 
a previous history of CVD (Sarnak et al. 2003). Many 
authors believe that CKD itself is a cardiovascular disease 
equivalent (Tonelli et al. 2001).  Risk factors that are 
uniquely associated with CKD include anaemia, left 
ventricular hypertrophy, hypoalbuminaemia and deranged 
calcium-phosphate metabolism. Additionally, there is now 
much evidence to indicate that CKD itself is a chronic low-
grade proinflammatory state that promotes atherosclerosis 
and CVD. Inflammatory biomarkers such as highly-
sensitive C reactive protein (hs-CRP), cystatin C (CysC) 
and more recently, asymmetrical dimetylarginine (ADMA) 
and symmetrical dimethylarginine (SDMA) were being 
investigated as CVD marker in CKD patients (Abraham et 
al. 2009; Carmen et al. 2011; Schwedhelm et al. 2011; 
Zoccali et al. 2001). 
 CRP is a protein well established to decrease endothelial 
nitric oxide synthase expression and contributes to the 
development of atherosclerosis. CKD patients demonstrate 
signs of inflammation even before the initiation of dialysis. 
There are a strong relationships between renal function 
and various inflammatory biomarkers, such as CRP, IL-6 
and TNF-a, suggesting that the kidney plays a role in the 
clearance of pro-inflammatory cytokines (Descamps-
Latscha & Witko-Sarsat 2001; Pecoits-Filho et al. 2002).
CysC is a 122-amino acid that belongs to a family of 
potent, noncovalent, competitive inhibitors of mammalian 
lysosomal cysteine proteinases. Unlike serum creatinine, 
CysC has a constant rate of production independent of 
age, sex or muscle mass and may be a better marker for 
renal function (Coll et al. 2000; Marwyne et al. 2011; 
Moran et al. 2008). Several recent publications have also 
demonstrated that CysC was superior to serum creatinine 
for prediction of all-cause mortality, cardiovascular events 
and incident congestive heart failure in elderly community-
based cohorts (Joachim et al. 2007). 
 ADMA is a natural endogenous inhibitor for nitric oxide 
production which is a vasculo-protective substance. By 
inhibiting nitric oxide formation, ADMA causes endothelial 
dysfunction, vasoconstriction, hypertension and worsening 
of atherosclerosis. Levels of ADMA and its isomer SDMA, 
which does not inhibit nitric oxide synthesis, are both 
elevated in patients with kidney disease. Data from 
prospective clinical trials in patients with CKD suggest 
that ADMA is an independent marker of progression of 
renal dysfunction, vascular complications, cardiovascular 
disease and death (Schwedhelm et al. 2011; Zoccali et al. 
2001).
 Unfortunately, as CKD is a heterogenous disease 
with many comorbidities, there was no single biomarker 
had been used as a surrogate marker for CVD in CKD 
patients in clinical setting. Usually the detection for CVD 
in CKD patients will only be done when the patients are 
symptomatic and too late. Hence, it is important to find a 
suitable CVD biomarker in CKD patients so prevention and 
treatment can be institute early.  The objectives of this study 
were to determine serum levels of hs-CRP, CysC, ADMA 
and SDMA in patients with CKD with and without CVD. We 
also wanted to determine the association between these 
biomarkers with different stages of CKD. 
PATIENTS AND METHODS
This was a case-control study between CKD patients with 
and without CVD. The patients were matched based on 
their stages of CKD and comorbidities i.e. diabetes mellitus, 
hypertension, dyslipidaemia and history of smoking. Both 
control and the case patients were recruited consecutively 
from the nephrology clinic at Universiti Kebangsaan 
Malaysia Medical Centre. All consented adult patients 
with stage 2 to 4 CKD were eligible for this study.  Pregnant 
patients and patients with a life expectancy less than 2 years 
and psychiatric disorder that might interfere with patient 
compliance to clinic visits were excluded from the study.
 Baseline demographic data and routine blood and 
non-invasive cardiovascular investigations were performed 
as per standard care. The study proposal was reviewed, 
approved and granted by the Ethics and Research 
Committee of the Universiti Kebangsaan Malaysia Medical 
Centre (Study code: UKM-DLP-2011-030). Informed 
consents were taken from all the study patients.
 Cardiovascular disease was defined when one or 
more of the following conditions occur: Acute coronary 
syndrome, ischaemic heart disease, congestive cardiac 
failure, transient ischaemic attack, stroke, peripheral 
vascular disease and abdominal angina (Shanti et al. 2011).
MEASUREMENTS METHODS 
Biomarkers were measures after consents were taken 
from the patients. Five mL of plasma non-fasting 
blood samples for biomarkers levels were kept in 
EDTA-plasma tubes at -20oC. ADMA and SDMA were 
measured using ELISA essay kits (Eagle Bioscience 
Inc, Nashua NH). Hs-CRP was measured using latex 
enhanced immunoturbidimetric (Roche Diagnostic Corp) 
using Cobra Intergral Instruments. CysC was measured 
using particle enhanced immunonephelometry technique 
on the Behring nephelometer systems
SAMPLE SIZE CALCULATION
Prior data indicated that the probability of exposure among 
controls was 0.2 (Schwedhelm et al. 2011). Using the 
formula by Kelsey, we needed a total sample size of 60 
patients to be able to reject the null hypothesis that this 
odds ratio equals 5 with a probability power of study of 0.8. 
STATISTICAL ANALYSIS
All numerical data was subjected to normality testing 
using Kolmogorov Smirnov. Normally distributed data 
was expressed as mean ± standard deviation whereas 
non-normally distributed data was expressed as median 
(interquartile range).  For normally distributed data, 
parametric test with Students’ T test was used. For  non-
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normally distributed data, the mean of the two groups were 
compared using non-parametric tests - Mann-Whitney U, 
Chi-Square test and Fisher’s Exact test for qualitative data 
and data for each group was compared using analysis of 
variance (ANOVA). For any skewed distribution, multiple 
linear regressions were used. The statistical package IBM 
SPSS version 19.0 (IBM Corp, New York, USA) was used 
for the above analysis. Statistical significance was taken 
as p<0.05.
RESULTS
Sixty two CKD patients with a mean age of 60.3 ± 10.4 
years were recruited, 47 patients were men and 15 patients 
were women. Nine had stage 2 CKD, 33 had stage 3 and 
20 patients with stage 4. Of these, 23 (37.1%) had CVD, 
23 (37.1%) had diabetes mellitus and 58 (93.5%) had 
dyslipidaemia. 
 Table 1 shows their baseline demographic parameters 
in patients with and without CVD. Patients with CVD were 
significantly older and had higher systolic blood pressure 
than patients without CVD. Other parameters were not 
significant between the both groups. Using multivariate 
logistic regression, only DM were found to be predictor 
of CVD (Adjusted OR: 8.04, 95% CI 1.25-51.77, p<0.05) 
(Table 2). 
 Table 3 shows investigations results between the 
2 groups. In diabetic patients, there was no significant 
TABLE 1. Demographic parameters in between CVD and non CVD groups
Parameters CVD (n=23) No CVD (n=39) p value
Age (years) 64.1 ± 8.0 58.1 ± 11.1 0.027*
Gender (%)
          Male
          Female
19 (83)
4 (17)
28(72)
11(28)
0.378
Race (%)
         Malay
         Chinese
         Indian
8 (35)
15 (65)
0 (0)
22(57)
15(38)
2(5)
0.094
Diabetes mellitus (%)
         Yes
         No
12(52)
11(48)
11(28)
28(72)
0.059
Hypertension (%)
         Yes
         No
21(91)
2(9)
37(95)
2(5)
0.581
Dyslipidaemia (%)
         Yes
         No
21(91)
2(9)
37(95)
2(5)
0.581
Smoking status (%)
         Yes
         No
         Ex-smoker
1(4)
18(78)
4(18)
1(3)
35(90)
3(7)
0.456
RAAS blocker (%)
         Yes 
          No
13(57)
10(43)
23(59)
16(41)
0.850
Statin (%)
         Yes
          No
18(78)
5(22)
28(72)
11(28)
0.574
Fibrate (%)
         Yes
          No
5(22)
18(78)
4(10)
35(90)
0.215
Systolic BP (mmHg)
Diastolic BP (mmHg)
MAP (mmHg)
BMI (kg/m2)
139.4 ± 16.2
85.4 ± 13.4
102.9 ± 14.1
25.6   ± 3.7
129.4 ± 14.8
80.1 ± 10.8
96.1 ± 11.9
26.8   ± 4.2
0.018*
0.098
0.054
0.363
* statistically significant
RAAS: Renin-angiotensin-aldosterone system
BP: Blood pressure
MAP: Mean arterial Pressure
BMI : Body mass index
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difference between fasting blood glucose (8.2 ± 2.8 vs 7.5 
±1.8 mmol/L, p=0.482) and HbA1c (7.2±1.6 vs 8.1±2.0%, 
p=0.372) in between patients with CVD and non CVD, 
respectively. Table 4 shows the association between serum 
levels of hs-CRP, CysC, ADMA and SDMA with stages of 
CKD.
DISCUSSION
CKD is a worldwide epidemic and in Malaysia, the 
prevalence of all stages of CKD was about 9% and only 
4% of them are aware of the diagnosis. In this study the 
factors associated with increase risk of CKD were age, 
hypertension, diabetes mellitus and dyslipidaemia (Lai 
et al. 2013).  The prevalence of hypertension and type 2 
diabetes mellitus in Malaysia for aged 30 and above was 
43.5% (Clinical Practice Guidelines 2013) and 20.8% 
(Clinical Practice Guidelines 2015), respectively. As these 
rates are increasing in trend, we foresee the prevalence of 
CKD will increase in the future.
 CVD risk is extremely high in CKD patients and CKD 
is regarded as CVD equivalent (Tonelli et al. 2001).  In this 
country, main cause of mortality in dialysis patient was CVD 
(Wong & Ong 2013).  This unique and strong relationship 
most probably due to a strong relationship between the two 
organs in cardio-renal complex and because they shared 
many similar risk factors like age, diabetes mellitus and 
hypertension. 
 There are few CVD risk factors that are uniquely 
associated with CKD include anaemia, left ventricular 
hypertrophy, hypoalbuminaemia and deranged calcium-
phosphate metabolism. Unfortunately, diagnosing CKD 
patients with CVD can be very challenging. Due to a 
very high incidence of CVD in CKD patients, the negative 
predictive value of many screening diagnostic non-invasive 
tests were diminished. The risk of contrast induced 
nephropathy limited the use of CT scan angiography and 
coronary angiogram procedures (Herzog et al. 2011). 
Cardiac markers like troponin T and I in acute setting were 
difficult to interpret in CKD patients as these markers can 
be elevated in the absence of true myocardial necrosis 
(Herzog et al. 2011).
 Does everybody with CKD need a cardiology 
assessment? It is very time consuming and not cost-
effective. We desperately need a CVD biomarker that is 
specific for CKD patients. Ideally, these biomarkers should 
TABLE 2. Multivariate analysis of demographic parameters
Parameter Adjusted Odd Ratio 95% CI p value 
Age
Gender
Diabetes mellitus
Hypertension
Dyslipidaemia
Body mass index
1.08
9.04
8.04
0.31
0.64
0.85
0.97-1.20
0.59-139.82
1.25-51.77
0.01-12.83
0.00-450.10
0.66-1.08
0.132
0.115
0.028*
0.313
0.893
0.184
* statistically significant
TABLE 3. Investigation results in between CVD and non CVD groups
Parameters CVD (n=23) No CVD( n=39) p value
Hb (g/dL)
Cholesterol (mmol/L)
Tg ( mmol/L)
LDL ( mmol/L)
HDL ( mmol/L)
Uric acid (mmol/L)
Fasting blood sugar (mmol/L)
Creatinine (mmol/L)
eGFR
Cystatin C (mg/L)
hsCRP (mg/L)
ADMA (mmol/L)
SDMA (mmol/L)
Urine PCI
12.1 ± 3.2
4.9 ± 0.7
1.3(1.1-1.7)
2.8 ± 0.6
1.3 ± 0.4
480.9 ± 134.8
7.1 ± 2.7
185.0±54.1
33.7 ± 12.2
1.8 ± 0.5
3.7(0.8-7.7)
0.86(0.77-0.92)
1.9±0.3
0.04(0.02-0.21)
13.2 ± 1.6
5.4 ± 1.3
1.8(1.4-2.3)
3.2 ± 1.1
1.3 ± 0.3
456.1± 102.7
6.3±  1.6
154.1±54.4
42.2 ± 14.5
1.7 ± 0.8
1.5(0.5-3.5)
0.85(0.77-0.94)
1.7±0.5
0.06(0.02-0.13)
0.090
0.077
0.020*
0.161
0.589
0.438
0.340
0.035*
0.023*
0.777
0.246
0.987
0.059
0.464
* statistically significant
Hb : Haemoglobin
Tg: Triglyceride
eGFR : estimated glomerular filtration rate in ml/min/1.73m2
LDL : Low density lipoprotein
HDL : High density lipoprotein
Urine PCI : Urine Protein Creatinine index in g/mmol creatinine
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help stratify CKD patients with varying degrees of risk for 
CVD so that early primary preventive strategies can be 
more effectively implemented. In this study, we looked 
at few potential CVD biomarkers viz hs-CRP, ADMA, SDMA 
and CysC in CKD patients. We have chosen stage 2-4 CKD 
as we could not rule out CVD confidently in stage 5 CKD 
patients and we are not sure the effects of dialysis on the 
clearance of these new biomarkers.
 In our study, age was a very important risk factor for 
CVD. A large cohort study of 3.6 million subjects aged 
more than 40 years old, age is an important independent 
risk factor for CVD (Savji et al. 2013). There was a 
clear sign that Malaysian population is moving to aging 
population (Wan-Ibrahim et al. 2014) and we are expecting 
higher prevalence of CKD and CVD in the future. Another 
important CVD risk factor is hypertension in particular 
systolic hypertension. Hypertension is well established 
risk factor for artherosclerotic diseases including coronary 
artery disease, ischaemic stroke and peripheral vascular 
disease.   Hypertension is frequently associated with CKD 
and it can be the cause or the consequence of CKD (Ravera 
et al. 2006). Controlling blood pressure especially systolic 
blood pressure can be difficult in CKD patients (Coresh 
et al. 2001; Ravera et al. 2006; Tonelli et al. 2001). Most 
CKD patients are volume overload (Hung et al. 2014; 
Wieskotten et al. 2008) and it is a risk factor for CVD.
 We did not find total cholesterol and low density 
lipoprotein as CVD biomarkers in our study. Instead 
triglyceride was found to be significant lower in CKD 
patients with CVD. Analyzing lipid profile can be difficult 
in CKD patients. Most of patients were asked to limit their 
protein intake and majority of them were put on statin. 
Only few patients were put on fibrates as fibrates may 
cause elevated serum creatinine. Although the importance 
of the elevated serum creatinine is still debatable, many 
nephrologists are not willing to prescribe fibrates. 
 We found that serum creatinine and estimated 
glomerular filtration rate (eGFR) were predictors of CVD. 
Other biomarkers were not important in predicting CVD in 
CKD patients. Inulin clearance has long been regarded as 
the gold standard for measuring GFR, but the procedure is 
costly, time consuming and difficult to perform (Beddhu 
et al. 2003). Creatinine has many advantages as a filtration 
marker and its measurement is cost effective (Beddhu et al. 
2003). eGFR was calculated using Chronic Kidney Disease 
Epidemiology Collaboration (CKD-EPI) equation based on 
serum ceatinine. As serum creatinine and eGFR are markers 
of renal function, our findings are in accordance with 
the evidence that CKD itself is a cardiovascular disease 
equivalent (Tonelli et al. 2001).  
 Serum CysC is a new and promising marker for 
kidney dysfunction (Coll et al. 2000; Marwyne et al. 2011; 
Moran et al. 2008). Numerous studies had found CysC 
to be a better marker of GFR than creatinine. We have 
proven that CysC is a better kidney function marker in 
our population especially in obese individual (Marwyne 
et al. 2011). There are many studies looking as CysC as 
a cardiac biomarker (Joachim et al. 2006; Moran et al. 
2008). Unfortunately, we did not manage to prove that 
CysC as an important marker for CVD in CKD patients. 
Logically if CysC is a marker for renal function, it should 
be a good marker to predict CVD in CKD patients such 
as serum creatinine and eGFR. Our results can partly 
be explained as there are recent evidences showed that 
genetic polymorphism affect CysC plasma concentration 
(Akerblom et al. 2014) and CysC may not predict the 
development of CVD independently (Patrik et al. 2015). 
 We failed to show that ADMA and SDMA, the two 
new cardiovascular markers are important markers in our 
CKD population. Initial studies showed that promising 
findings of these endothelial marker in the pathogenesis 
of atherosclerotic plaque. Unfortunately, the clinical 
utility of these markers are still uncertain and they were 
not routinely measured in clinical setting. Hs-CRP plays 
an important role in inflammation and propagation of 
atherosclerotic disease. Unfortunately, we found that is not 
useful in predicting CVD in our CVD patients. We also found 
that SDMA significantly increase with worsening of renal 
function, nevertheless it has no effect on cardiovascular 
prediction. As we know renin-angiotensin-aldosterone 
system plays an important role in the development 
of vascular remodeling, atherosclerotic plaque and 
inflammation (Duprez 2006). Hence, the negative 
correlation findings in our study could be confounded by 
many of our patients was on renin-angiotensin-aldosterone 
blockers. 
 Surprisingly we do not see any correlation as 
proteinuria and CVD in our population. As we know renin-
angiotensin-aldosterone blockers reduces proteinuria in 
CKD patients. Thus, these findings might also be because 
more than half the patients were on renin-angiotensin-
aldosterone blockers in this study. 
TABLE 4. Association between the biomarkers with stages of CKD
Stage 2 Stage 3 Stage 4 p
eGFR
hsCRP (mg/L)
CysC (mg/L)
ADMA (mmol/L)
SDMA (mmol/L)
63.6 ± 4.4
3.27±  2.87
1.05±  0.11
0.76 ± 0.20
1.34 ± 0.38
41.1  ±8.3
3.21 ± 3.81
1.61 ± 0.65
0.82 ± 0.25
1.81±  0.32
24.6 ± 3.4
7.00  ± 11.50
2.21 ± 0.47
0.96 ± 0.35
2.02 ± 0.43
<0.001
0.172
<0.001
0.142
<0.001
*statistically significant
eGFR : estimated glomerular filtration rate in mL/min/1.73 m2
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 There were few limitations of this study. The definition 
of CVD in our study depended on previous history and we 
might miss patients with asymptomatic CVD. This study 
was also a small case-control study that unable to make a 
strong recommendation for clinical practice. Nevertheless 
this study was robust enough and showed that renal 
function measured by serum creatinine and eGFR were 
that most powerful predictor for CVD. Serum creatinine 
measurement is relatively cheap and eGFR can be calculated 
easily. Renal function should be the determined in all 
patients at risk of CVD. Patient with renal failure should be 
stratified to have higher risk of CVD. This finding is very 
important and in accordance with the recommendation that 
CKD is a CVD equivalent. Patient with CKD should receive 
initial baseline non-invasive cardiology investigation like 
electrocardiogram and exercise stress test. 
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